Show simple item record

dc.contributor.authorGhasemi, M.en_US
dc.contributor.authorErturk, M.en_US
dc.contributor.authorBuruk, K.en_US
dc.contributor.authorSonmez, M.en_US
dc.date.accessioned2016-02-08T09:40:15Z
dc.date.available2016-02-08T09:40:15Z
dc.date.issued2013en_US
dc.identifier.issn14653249
dc.identifier.urihttp://hdl.handle.net/11693/21049
dc.description.abstractBackground aims. Dendritic cells (DCs) are the most potent antigen presenting cells of the immune system and have been under intense study with regard to their use in immunotherapy against cancer and infectious disease agents. In the present study, DCs were employed to assess their value in protection against live virus challenge in an experimental model using lethal and latent herpes simplex virus (HSV) infection in Balb/c mice. Methods. DCs obtained ex vivo in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4 were loaded with HSV-1 proteins (DC/HSV-1 vaccine). Groups of mice were vaccinated twice, 7 days apart, via subcutaneous, intraperitoneal or intramuscular routes with DC/HSV-1 and with mock (DC without virus protein) and positive (alum adjuvanted HSV-1 proteins [HSV-1/ALH]) control vaccines. After measuring anti-HSV-1 antibody levels in blood samples, mice were given live HSV-1 intraperitoneally or via ear pinna to assess the protection level of the vaccines with respect to lethal or latent infection challenge. Results. Intramuscular, but not subcutaneous or intraperitoneal, administration of DC/HSV-1 vaccine provided complete protection against lethal challenge and establishment of latent infection as assessed by death and virus recovery from the trigeminal ganglia. It was also shown that the immunity was not associated with antibody production because DC/HSV-1 vaccine, as opposed to HSV-1/ALH vaccine, produced very little, if any, HSV-1-specific antibody. Conclusions. Overall, our results may have some impact on the design of vaccines against genital HSV as well as chronic viral infections such as hepatitis B virus, hepatitis C virus and human immunodeficiency virus. © 2013, International Society for Cellular Therapy.en_US
dc.language.isoEnglishen_US
dc.source.titleCytotherapyen_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.jcyt.2012.11.012en_US
dc.subjectDendritic cellsen_US
dc.subjectHerpes simplex virusen_US
dc.subjectMiceen_US
dc.subjectVaccineen_US
dc.subjectdendritic cell vaccineen_US
dc.subjectgranulocyte macrophage colony stimulating factoren_US
dc.subjectherpes simplex vaccineen_US
dc.subjectinterleukin 4en_US
dc.subjectanimal cellen_US
dc.subjectanimal experimenten_US
dc.subjectanimal modelen_US
dc.subjectantibody productionen_US
dc.subjectarticleen_US
dc.subjectcontrolled studyen_US
dc.subjectex vivo studyen_US
dc.subjectherpes simplexen_US
dc.subjectimmunizationen_US
dc.subjectmouseen_US
dc.subjectnonhumanen_US
dc.subjectpriority journalen_US
dc.subjecttreatment responseen_US
dc.subjecttrigeminus ganglionen_US
dc.subjectvirus immunityen_US
dc.subjectAnimalsen_US
dc.subjectAntibodies, Viralen_US
dc.subjectDendritic Cellsen_US
dc.subjectGranulocyte-Macrophage Colony-Stimulating Factoren_US
dc.subjectHerpes Simplexen_US
dc.subjectHerpes Simplex Virus Vaccinesen_US
dc.subjectHumansen_US
dc.subjectImmunotherapyen_US
dc.subjectInterleukin-4en_US
dc.subjectMiceen_US
dc.subjectSimplexvirusen_US
dc.subjectViral Envelope Proteinsen_US
dc.titleInduction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cellsen_US
dc.typeArticleen_US
dc.departmentDepartment of Molecular Biology and Genetics
dc.citation.spage352en_US
dc.citation.epage361en_US
dc.citation.volumeNumber15en_US
dc.citation.issueNumber3en_US
dc.identifier.doi10.1016/j.jcyt.2012.11.012en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record